Summary
• Mereo BioPharma shares fell 1.9% to $0.28 after disappointing Phase 3 trial results for Setrusumab.
• Neither the ORBIT nor COSMIC studies achieved their primary endpoints, impacting investor sentiment.
• Analyst ratings are mixed, with one maintaining a “Buy” and another downgrading to “Market Perform” after the trial results.
Mereo BioPharma Group plc’s shares are down 1.9% during intraday trading, currently priced at $0.28. The stock’s movement comes after recent Phase 3 trial results from studies involving Setrusumab (UX143) for osteogenesis imperfecta were made public, failing to meet their primary endpoints.
Phase 3 Trial Results Disappoint Investors
On December 29, Mereo BioPharma announced that neither the ORBIT nor the COSMIC study achieved its primary endpoint of reducing the annualized clinical fracture rate compared to placebo or bisphosphonates. This news likely contributed to the stock’s downward pressure as investors evaluated the implications on the company’s therapeutic potential and commercial prospects.
In the last earnings report dated November 10, the company reported actual earnings of -$0.01 per share, exceeding analyst estimates of -$0.0035. Despite this unexpected surprise of 186%, Mereo BioPharma has struggled with recent performance metrics, as reflected in its year-to-date decline of 91.9%. Similarly, the 52-week range shows the stock has closed to a high of $0.49 and a low of $0.12, illustrating significant volatility.
Analyst Sentiment Shifts
The latest analyst ratings provide a mixed view. Julian Harrison from BTIG maintained a “Buy” rating with a price target of $6, reflecting a degree of optimism regarding Mereo’s long-term potential. Conversely, Cory Jubinville of LifeSci Capital downgraded his rating from “Outperform” to “Market Perform,” indicating caution following the recent trial outcomes.
Market Performance Overview
Trading activity has seen significant volume, with approximately 37 million shares exchanged, far exceeding the average volume of 5.6 million over the past three months. Technically, Mereo’s price remains heavily deviated from its simple moving averages, showing an SMA20 down by 85.8%, SMA50 down by 85.3%, and SMA200 down by 86.4%. The current Relative Strength Index (RSI) stands at 19.02, indicating that the stock may be oversold.
Outlook
Mereo BioPharma continues to face headwinds, primarily due to trial results that did not meet expectations. As the company navigates through these challenges, market participants will be closely watching for future developments or strategic changes that could affect its trajectory.